Oxford BioDynamics Plc (LON:OBD – Get Free Report) fell 10.9% during trading on Tuesday . The stock traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.47 ($0.01). 585,995 shares were traded during mid-day trading, a decline of 98% from the average session volume of 26,710,965 shares. The stock had previously closed at GBX 0.53 ($0.01).
Analysts Set New Price Targets
Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.
Read Our Latest Research Report on OBD
Oxford BioDynamics Stock Down 12.8 %
Oxford BioDynamics (LON:OBD – Get Free Report) last issued its earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.
About Oxford BioDynamics
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
See Also
- Five stocks we like better than Oxford BioDynamics
- When to Sell a Stock for Profit or Loss
- Microsoft’s AI Strategy Eases Analyst Concerns—Is It a Buy?
- Profitably Trade Stocks at 52-Week Highs
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
- What is an Earnings Surprise?
- ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.